百本医护(02293)发布公告，于2025年4月14日，集团透过于联交所进行场内交易购入合共8600股SPDR金ETF股份，总代价约为1997万港元(不包括交易成本)，代表每股股份约为2322港元。

在收购事项日期之前的12个月期间内，集团购入合共11965股SPDR金ETF股份，总代价约为2220万港元(不包括交易成本)，代表每股股份约为1855港元。

于该等收购事项之后，集团合共持有20565股SPDR金ETF股份，占SPDR金ETF全部已发行股本约0.00632%。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.